Capricor Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Capricor Therapeutics, Inc.
Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?
Eisai is testing its anti-tau antibody in combination with the anti-amyloid therapy Leqembi, and earlier-stage programs targeting TrkA, EphA4 and TREM2 offer new approaches and combo potential.
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
With the world’s first exclusively intranasal COVID-19 vaccine against COVID-19 getting restricted use approval in India, Bharat Biotech/Washington University St. Louis offer an easy-to-use immunization option. But is it too little too late?
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Capricor Inc.
- Nile Therapeutics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.